# Isai Peimer

> Isai Peimer is a Series D investor at Surveyor Capital backing Biopharma and Health Care. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital)
- Location: Washington, United States
- Total investments: 2
- Last investment: Nov 2012
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/isai-peimer/1/1a4/66b
- X (Twitter): http://twitter.com/IsaiPeimer
- Website: http://www.medimmuneventures.com

Isai Peimer is a Senior Analyst at Surveyor Capital. He attended The Tuck School of Business at Dartmouth.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 50% |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 1 | 50% |
| Funding Round | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ambit Biosciences | Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3)inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon. | $50M |  | Nov 06, 2012 |  |
| Ambit Biosciences | Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit's lead compound, AC220, is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3)inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing AC220 in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to AC220, Ambit's clinical pipeline includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. Ambit also has a pipeline of preclinical candidates which includes CEP-32496, a BRAF inhibitor licensed to Cephalon. | $30M | Series D | Jun 10, 2011 |  |

2 of 2 investments shown.

## Co-investors
- [Forward Ventures](https://shizune.co/investors/profile/forward-ventures) — VC Fund, 2 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 2 deals together
- [GrowthWorks Capital](https://shizune.co/investors/profile/growthworks) — VC Fund, 2 deals together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 2 deals together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together
- [Novaquest Capital Management](https://shizune.co/investors/profile/novaquest-capital-management) — VC Fund, 1 deal together

## About Surveyor Capital

VC Fund · Chicago, United States

Surveyor Capital is a fundamental equities business. Surveyor’s sector-aligned investment teams aim to generate alpha through a deep understanding of each company’s strategy, management teams, drivers of performance, and cyclical and secular industry trends over the medium and long term.

5 contacts available at Surveyor Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Isai Peimer | Senior Analyst | https://shizune.co/investors/profile/isai-peimer |
| Joshua A.W. Mosberg | Analyst | https://shizune.co/investors/profile/joshua-a-w-mosberg |
| Brad Lau | Deputy Chief Operating Officer | https://shizune.co/investors/profile/brad-lau |
| Daniel Krizek | Portfolio Manager | https://shizune.co/investors/profile/daniel-krizek |
| Gerald A. Beeson | Senior Managing Director, Chief Operating Officer | https://shizune.co/investors/profile/gerald-a-beeson |

## Similar investors

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

## FAQ

### What does Isai Peimer invest in?

Isai Peimer invests primarily in Biopharma, Health Care and Biotechnology startups, most often at Series D and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Isai Peimer last invest?

The most recent investment recorded for Isai Peimer closed in Nov 2012. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co